Longevity investing requires pragmatic execution, not just optimism. Our just-launched Fund II reflects the same investment principles that shaped our first fund: rigorous scientific diligence as the foundation of risk management, early translational data as validation, and partnerships with teams capable of advancing technologies from concept to clinic. Building on Fund I’s success—zero write-offs and a portfolio advancing from concept to clinic—this fund emphasizes that scientific rigor is the best risk management.
Our first commitment from Fund II is Trogenix's €80 million Series A, led by IQ Capital with participation from 4BIO Capital, Cancer Research Horizons, the Brain Tumor Investment Fund, Eli Lilly and Company, Meltwind Advisory LLP, and Calculus Capital.
Trogenix, an Edinburgh-based company, is developing potentially disease-modifying therapies targeting aggressive tumors, beginning with glioblastoma. Their Odysseus platform delivers genetic payloads designed to expose tumors to immune recognition while preserving healthy tissue, a mechanism aimed at durable, potentially one-time therapeutic outcomes.
Read more by David Cendon Garcia in EU-Startups here.
Our first commitment from Fund II is Trogenix's €80 million Series A, led by IQ Capital with participation from 4BIO Capital, Cancer Research Horizons, the Brain Tumor Investment Fund, Eli Lilly and Company, Meltwind Advisory LLP, and Calculus Capital.
Trogenix, an Edinburgh-based company, is developing potentially disease-modifying therapies targeting aggressive tumors, beginning with glioblastoma. Their Odysseus platform delivers genetic payloads designed to expose tumors to immune recognition while preserving healthy tissue, a mechanism aimed at durable, potentially one-time therapeutic outcomes.
Read more by David Cendon Garcia in EU-Startups here.